(R)-1-tert-butyl-N-(2-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-6,7,8,9-tetrahydro-5H-benzo[7]annulen-5-yl)-1H-1,2,3-triazole-4-carboxamide

ID: ALA5085931

Chembl Id: CHEMBL5085931

PubChem CID: 135356071

Max Phase: Preclinical

Molecular Formula: C26H31N9O

Molecular Weight: 485.60

Molecule Type: Unknown

Names and Identifiers

Canonical SMILES:  Cn1cc(Nc2nccc(-c3ccc4c(c3)CCCC[C@H]4NC(=O)c3cn(C(C)(C)C)nn3)n2)cn1

Standard InChI:  InChI=1S/C26H31N9O/c1-26(2,3)35-16-23(32-33-35)24(36)30-22-8-6-5-7-17-13-18(9-10-20(17)22)21-11-12-27-25(31-21)29-19-14-28-34(4)15-19/h9-16,22H,5-8H2,1-4H3,(H,30,36)(H,27,29,31)/t22-/m1/s1

Standard InChI Key:  YTDWCUZDAXLKFU-JOCHJYFZSA-N

Alternative Forms

1. Parent:

   

   ALA5085931

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 485.60

Molecular Weight (Monoisotopic): 485.2652

AlogP: 4.16

#Rotatable Bonds: 5

Polar Surface Area: 115.44

Molecular Species: NEUTRAL

HBA: 9

HBD: 2

#RO5 Violations: 0

HBA (Lipinski): 10

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 10.69

CX Basic pKa: 1.95

CX LogP: 4.35

CX LogD: 4.35

Aromatic Rings: 4

Heavy Atoms: 36

QED Weighted: 0.41

Np Likeness Score: -1.74

References

1. Hopkins BT, Bame E, Bajrami B, Black C, Bohnert T, Boiselle C, Burdette D, Burns JC, Delva L, Donaldson D, Grater R, Gu C, Hoemberger M, Johnson J, Kapadnis S, King K, Lulla M, Ma B, Marx I, Magee T, Meissner R, Metrick CM, Mingueneau M, Murugan P, Otipoby KL, Polack E, Poreci U, Prince R, Roach AM, Rowbottom C, Santoro JC, Schroeder P, Tang H, Tien E, Zhang F, Lyssikatos J..  (2022)  Discovery and Preclinical Characterization of BIIB091, a Reversible, Selective BTK Inhibitor for the Treatment of Multiple Sclerosis.,  65  (2.0): [PMID:34734694] [10.1021/acs.jmedchem.1c00926]

Source

Source(1):

• Scientific Literature